Semaglutide: Molecular Action and Formulation-Specific Evidence

GLP-1 is the signal; semaglutide is the molecule

Semaglutide is a peptide medicine that activates the glucagon-like peptide-1 receptor. GLP-1 is a naturally occurring hormone released from the intestine in response to nutrients; it is not another chemical name for semaglutide. A receptor agonist binds to a receptor and activates its signalling, allowing a modified molecule to engage a pathway normally used by the body's own hormone.

Semaglutide's molecular modifications reduce enzymatic breakdown and promote albumin binding, extending exposure compared with native GLP-1. These properties help explain its pharmacology, but they do not establish that every preparation bearing the molecule's name produces the same exposure. The EMA Wegovy assessment provides regulatory and product context for a specific evaluated medicine, rather than evidence validating unrelated research products.

Why one receptor can affect several outcomes

GLP-1 receptors participate in both appetite regulation and glucose control. Semaglutide can reduce hunger and energy intake through appetite-related signalling. In the pancreas, it increases insulin secretion in a glucose-dependent manner and reduces glucagon secretion when glucose is elevated. These actions influence glucose handling without making weight change and blood-glucose change interchangeable outcomes.

Delayed gastric emptying is another pharmacological effect, but it should not be treated as a complete explanation for sustained weight reduction. Appetite, food intake and gastrointestinal physiology are connected but distinct processes. A clinical weight measurement records their net consequences; it does not identify how much each mechanism contributed.

STEP 1: what the weight result actually represents

STEP 1 enrolled 1,961 adults with obesity, or overweight with an associated condition, without diabetes. Participants were randomly assigned to subcutaneous semaglutide, with a target study dose of 2.4 mg, or placebo. Both groups received lifestyle intervention.

At 68 weeks, estimated mean body-weight change was −14.9% with semaglutide and −2.4% with placebo under the treatment-policy estimand. This analysis addressed the effect of assignment to treatment regardless of treatment discontinuation or rescue intervention. The difference was approximately 12.4 percentage points using the trial's unrounded estimates.

These are group averages expressed relative to starting weight, not predicted losses for each individual. The placebo comparison also matters: the trial estimated an additional effect in a setting where both groups received lifestyle support, rather than comparing medicine with no intervention at all. Gastrointestinal adverse events were more frequent with semaglutide, so the efficacy finding cannot be separated from tolerability and discontinuation.

SELECT asked a different question

Weight reduction does not itself prove fewer cardiovascular events. SELECT tested that outcome directly in 17,604 adults aged at least 45 years with a BMI of at least 27, established cardiovascular disease and no diabetes.

Over a mean follow-up of 39.8 months, cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% of participants assigned to subcutaneous semaglutide 2.4 mg and 8.0% assigned to placebo. The hazard ratio was 0.80, commonly described as a 20% relative reduction; the observed event proportions differed by 1.5 percentage points.

The result applies to this high-risk population and evaluated formulation. It does not establish the same cardiovascular effect in people without established cardiovascular disease, or for an oral formulation merely because the active molecule has the same name.

Reading evidence without flattening the distinctions

Molecular identity, formulation performance and clinical outcomes answer different questions. A research vial is not made equivalent to an approved medicine by citing STEP 1 or SELECT. Likewise, analytical purity alone cannot demonstrate clinical performance.

The practical reading rule is to keep four details attached to every result: the formulation, the population, the endpoint and the analysis. Our peptide-testing guide explains the separate evidence needed to interpret analytical reports.